Menu ×


Conjunctivitis Treatment Market Analysis by Drug Class (Antibiotics, Antiviral, Antiallergic, Artificial Tears, and Others); by Disease Type (Bacterial, Chemical, Viral and Allergic Conjunctivitis); by Route of Administration (Oral and Topical); and by End User (Hospital, Online, and Retail Pharmacies, and Drug Stores) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • Novartis Pharmaceutical Corporation acquired Kedalion Therapeutics and its AcuStream technology, a novel device to improve the Novartis ophthalmic portfolio.

  • AbbVie Inc. declared the U.S Food and Drug Administration (FDA) approval of VUITY, a pilocarpine HCl ophthalmic solution of 1.25 % used for the treatment of presbyopia that affects 128 million Americans.

Global Conjunctivitis Treatment Market Highlights Over 2023 – 2033

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 5 Billion

Forecast Year Market Size (2033)

~ USD 8 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)


The global conjunctivitis treatment market is estimated to garner a revenue of ~USD 8 Billion by the end of 2033 by growing at a CAGR of ~4% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 5 Billion in the year 2023. Rising development & advancements in drug delivery methods for conjunctivitis treatment, and significant rise in healthcare expenditure is estimated to rise the market growth during the forecast period. The healthcare expenditure of the U.S in 2020 rose to 9.7% and reached USD 4.1 trillion i.e., USD 12,530 per individual.

conjunctivitis overview image

Get more information on this report:Download Sample PDF

Such ocular allergy needs to be treated as soon as a person feels constant itching in one or both eyes, blurred vision, severe pain, and the formation of some kind of crust over the eye in night. Therefore, the increasing prevalence of infectious conjunctivitis disease across the world is estimated to propel the growth of the conjunctivitis treatment market trend during the forecast period. As per the observations, the occurrence of conjunctivitis infection in the last 10 years was recognized in more than 20% of participants across the world.

Global Conjunctivitis Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Increasing Air Pollution Across the World – Exposure to indoor or outdoor air pollution can be harmful to human eyes. Tobacco smoking, cooking, and poor indoor ventilation cause eye disorders such as glaucoma, conjunctivitis, cataracts, and age-related macular degeneration. Air pollution accounts for 12% of deaths in the world and air pollution of particulate matter 2.5 leads to allergic conjunctivitis and glaucoma.

  • Growing Globalization and Industrialization – The number of industries across the globe grew from 320 million in 2020 to 330 million in 2021 as per the estimations.

  • Rising Cases of Neonatal Conjunctivitis – Ophthalmia neonatorum is one of the common conditions seen in nearly 1% to 12% of neonates in 2022.

  • Rising Burden of Bacterial Conjunctivitis Infection – The cost of treatment in the U.S for only bacterial conjunctivitis is USD 370-850 million per year.

  • Elevating Number of Hospitals & Healthcare Sectors – As per the U.S Bureau of Labor Statistics, in 2019 there were 13,944 hospitals for 328.2 million population.


  • More Adverse Effects of Drugs – Many times, some medication does not suit the sensitivity of the patient and results in some more harsh outcomes such as, rashes, temporary burning or stinging sensation in infected eye, and sometimes issue of unstable vision after using the prescribed eye drop or ointment. 
  • Lack of Visits to Healthcare
  • Stringent FDA Approvals

The global conjunctivitis treatment market is segmented and analyzed for demand and supply by drug class into antibiotics, antiviral, antiallergic, artificial tears, and others. Out of these, the antiallergic segment is anticipated to hold the largest market size by the end of 2033 increasing the use of these drugs in an allergic reaction, and the growing prevalence of allergies among people especially those who are prone to seasonal allergies. For instance, allergic conjunctivitis or allergic eye issue was seen in 40% of people in the U.S in 2020.

Global Conjunctivitis Treatment Market Regional Synopsis

The North America conjunctivitis treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033 on the back of the growing use of lenses. For instance, as per the estimations, nearly 60% of people aged 26-40 and 90% of people aged 70 wear corrective lenses. Furthermore, proliferating healthcare activities, and cumulative R & D activities in the region are boosting up the conjunctivitis treatment market size over the forecast period.

conjunctivitis market share image

Market Segmentation

Our in-depth analysis of the global conjunctivitis treatment market includes the following segments:



        By Drug Class

  • Antibiotics
  • Antiviral
  • Antiallergic
  • Artificial Tears
  • Others



       By Disease Type

  • Bacterial Conjunctivitis
  • Chemical Conjunctivitis
  • Viral Conjunctivitis
  • Allergic Conjunctivitis

       By Route Of Administration

  • Oral
  • Topical



         By End User

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Drug Stores

Top Featured Companies Dominating the Global Conjunctivitis Treatment Market

  • Novartis Pharmaceuticals Corporation

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Aurobindo Pharma
  • Cipla Inc.
  • Viatris Inc.
  • AKRON, Inc.
  • USV Private Limited
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Micro Labs Ltd.


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved